Press releasePRNewswire
Jazz Pharmaceuticals
JAZZ · NASDAQ
$213.76+$5.33 (+2.56%)TodayMarket closed ·
Prev close $208.43
Latest news
- NewsAvi Kapoor
Jim Cramer Gives Green Light To This Health Care Stock
- Press releaseGlobe Newswire
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
- NewsRadhika Anilkumar Nadig
Nvidia-Backed AI Drug Discovery Company Iambic Therapeutics Files for Nasdaq IPO, to Use Proceeds for Cancer Drug Development
- Press releasePRNewswire
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences
- Press releasePRNewswire
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
- Press releasePRNewswire
Ziihera® (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA
- Press releasePRNewswire
Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
- NewsAvi Kapoor
These Analysts Increase Their Forecasts On Jazz Pharmaceuticals
- Press releasePRNewswire
Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases
- NewsVandana Singh
What'sGoing On With AbCellera Biologics Stock On Tuesday?
- NewsVandana Singh
Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens
- Press releasePRNewswire
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
- Press releasePRNewswire
Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio
- NewsAvi Kapoor
These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results
- News
Jazz Pharmaceuticals Q2 Adj. EPS $5.71 Misses $6.18 Estimate, Sales $1.208B Beat $1.115B Estimate
- Press releasePRNewswire
Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results
- Press releasePRNewswire
Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026
- NewsVandana Singh
Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera Collaboration
- Press releaseBusiness Wire
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
- Press releasePRNewswire
Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
- Press releasePRNewswire
Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
- NewsPriya Nigam
Jazz Pharmaceuticals' New Cancer Drug Drives $1.3 Billion Opportunity, Says Analyst
- Press releasePRNewswire
Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia
- Press releasePRNewswire
Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
- Press releasePRNewswire
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
- News
Jazz Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript
- News
Jazz Pharmaceuticals Q1 Adj. EPS $6.34 Beats $4.57 Estimate, Sales $1.609B Beat $976.563M Estimate
- Press releasePRNewswire
Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
- News
Earnings Scheduled For May 5, 2026
- Press releasePRNewswire
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
- Press releasePRNewswire
Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026
- Press releasePRNewswire
Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
- Press releasePRNewswire
Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting
- Press releasePRNewswire
Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference
- Press releasePRNewswire
American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education
- Press releasePRNewswire
Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
- Press releasePRNewswire
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- NewsAvi Kapoor
Acadia Healthcare Posts Upbeat Q4 Earnings, Joins Circle Internet, Resideo Technologies And Other Big Stocks Moving Higher On Wednesday
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.